Annual report pursuant to Section 13 and 15(d)

Common Stock

Common Stock	12 Months Ended
Dec. 31, 2018
Equity [Abstract]
Common Stock	7. Common Stock As of December 31, 2018, the Company has authorized 100,000,000 shares of common stock, $0.001 par value per share. The Company had 29,938,363 and 24,274,494 shares issued and outstanding as of December 31, 2018 and 2017, respectively. The holders of common stock are entitled to one vote for each share of common stock held. On April 20, 2017, the Company closed on proceeds of $3,000,000 in a private placement offering of 416,667 shares of the Company’s common stock at a purchase price of $7.20 per share to three investors, which included our former Chairman Dr. Raymond F. Schinazi and OPKO Health, Inc., of which the Company’s director, Dr. Phillip Frost, is Chairman and Chief Executive Officer. On January 18, 2018, the Board of Directors of the Company filed an amendment (the “Amendment”) with the Delaware Secretary of State to effect a one-for-thirty reverse split of the Company’s common stock. The Amendment took effect on January 24, 2018. No fractional shares were issued or distributed as a result of the Amendment. There was no change in the par value of our common stock. In May 2018, the Company closed a public offering for gross proceeds and net proceeds (inclusive of the additional proceeds from the underwriter exercised from the overallotment options) of approximately $8,428,000 and $7,684,000, respectively. The Company sold 4,210,527 shares of common stock to the underwriter at approximately $1.767 per share, which the underwriter sold to the public at $1.90 per share and issued the underwriter a warrant to purchase 84,211 shares of common stock at $2.09 per share over a four-year period beginning October 27, 2018. On May 14, 2018, the underwriter exercised the option to purchase an additional 225,000 shares of common stock at $1.90 per share for additional gross proceeds and net proceeds of approximately $428,000 and $418,000, respectively, solely to cover overallotments. As of December 31, 2018, the underwriter has no further option to purchase additional shares. On May 21, 2018, the Company issued a total of 1,085,105 shares of common stock upon conversion of all outstanding 8% convertible notes. See Note 8 – Convertible Notes Payable. On August 6, 2018, the Company held its 2018 Annual Meeting of Shareholders and voted to reduce the number of shares of common stock, $0.001 par value per share, authorized from 800,000,000 to 100,000,000 shares.

Common Stock

12 Months Ended

Dec. 31, 2018

7. Common Stock

As of December 31, 2018, the Company has authorized 100,000,000 shares of common stock, $0.001 par value per share. The Company had 29,938,363 and 24,274,494 shares issued and outstanding as of December 31, 2018 and 2017, respectively.

The holders of common stock are entitled to one vote for each share of common stock held.

On April 20, 2017, the Company closed on proceeds of $3,000,000 in a private placement offering of 416,667 shares of the Company’s common stock at a purchase price of $7.20 per share to three investors, which included our former Chairman Dr. Raymond F. Schinazi and OPKO Health, Inc., of which the Company’s director, Dr. Phillip Frost, is Chairman and Chief Executive Officer.

On January 18, 2018, the Board of Directors of the Company filed an amendment (the “Amendment”) with the Delaware Secretary of State to effect a one-for-thirty reverse split of the Company’s common stock. The Amendment took effect on January 24, 2018. No fractional shares were issued or distributed as a result of the Amendment. There was no change in the par value of our common stock.

In May 2018, the Company closed a public offering for gross proceeds and net proceeds (inclusive of the additional proceeds from the underwriter exercised from the overallotment options) of approximately $8,428,000 and $7,684,000, respectively. The Company sold 4,210,527 shares of common stock to the underwriter at approximately $1.767 per share, which the underwriter sold to the public at $1.90 per share and issued the underwriter a warrant to purchase 84,211 shares of common stock at $2.09 per share over a four-year period beginning October 27, 2018. On May 14, 2018, the underwriter exercised the option to purchase an additional 225,000 shares of common stock at $1.90 per share for additional gross proceeds and net proceeds of approximately $428,000 and $418,000, respectively, solely to cover overallotments. As of December 31, 2018, the underwriter has no further option to purchase additional shares.

On May 21, 2018, the Company issued a total of 1,085,105 shares of common stock upon conversion of all outstanding 8% convertible notes. See Note 8 – Convertible Notes Payable.

On August 6, 2018, the Company held its 2018 Annual Meeting of Shareholders and voted to reduce the number of shares of common stock, $0.001 par value per share, authorized from 800,000,000 to 100,000,000 shares.